Update 2014: Advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD

Inflammatory Bowel Diseases

Volumn 21, Issue 2, 2015, Pages 445-452

  Amin, Jaimin ^a   Huang, Brian ^b   Yoon, Jessica ^b   Shih, David Q ^b  

^a OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

6 mercaptopurine; 6 thioguanine; Anti TNF; Azathioprine; Desensitization; Drug level; Inflammatory bowel disease; Mesalamine; Split dosing; Thiopurine

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; MERCAPTOPURINE; MESALAZINE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

DATA BASE; DESENSITIZATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG USE; EVIDENCE BASED PRACTICE; HUMAN; INFLAMMATORY BOWEL DISEASE; LYMPHOPROLIFERATIVE DISEASE; MEDLINE; PHYSICIAN; PRIORITY JOURNAL; PURINE METABOLISM; REVIEW; TREATMENT RESPONSE; DISEASE MANAGEMENT; INFLAMMATORY BOWEL DISEASES; PROGNOSIS; TIME;

6-MERCAPTOPURINE; AZATHIOPRINE; DISEASE MANAGEMENT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS; TIME FACTORS;

EID: 84927746303     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000197     Document Type: Review

References (95)

1. Carter MJ, Lobo AJ, Travis SP; IBD Section, BSoG. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 (suppl 5):V1-V16.
2. Chebli LA, Chaves LD, Pimentel FF, et al. Azathioprine maintains longterm steroid-free remission through 3 years in patients with steroiddependent ulcerative colitis. Inflamm Bowel Dis. 2010;16:613-619.
3. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed). 1982;284:1291-1292.
4. Korelitz BI, Present DH. Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Dig Dis Sci. 1985;30:58-64.
5. Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2013;4:Cd000545.
6. Timmer A, McDonald JW, Tsoulis DJ, et al. Azathioprine and 6- mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;9:CD000478.
7. Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:1743-1750.
8. Jharap B, Seinen ML, de Boer NK, et al. Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8-year intercept cohorts. Inflamm Bowel Dis. 2010;16:1541-1549.
9. Seinen ML, van Asseldonk DP, Mulder CJ, et al. Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice. J Gastrointestin Liver Dis. 2010;19:291-294.
10. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302:981-987.
11. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
12. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: A meta-analysis. Gastroenterology. 2006;130:1047-1053.
13. Hindorf U, Lindqvist M, Peterson C, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut. 2006;55:1423-1431.
14. Bowen DG, Selby WS. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig Dis Sci. 2000;45:1810-1813.
15. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133-1145.
16. Watanabe A, Hobara N, Nagashima H. Demonstration of enzymatic activity converting azathioprine to 6-mercaptopurine. Acta Med Okayama. 1978;32:173-179.
17. Derijks LJ, Gilissen LP, Hooymans PM, et al. Review article: Thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:715-729.
18. Welch J, Lennard L, Morton GC, et al. Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral dose. Ther Drug Monit. 1997;19:382-385.
19. Dubinsky MC, Feldman EJ, Abreu MT, et al. Thioguanine: A potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol. 2003;98:1058-1063.
20. Haglund S, Vikingsson S, Soderman J, et al. The role of inosine-5'- monophosphate dehydrogenase in thiopurine metabolism in patients with inflammatory bowel disease. Ther Drug Monit. 2011;33:200-208.
21. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut. 2001;48:642-646.
22. Deshpande AR, Abreu MT. Optimizing therapy with 6-mercaptopurine and azathioprine: To measure or not to measure? Therap Adv Gastroenterol. 2010;3:275-279.
23. Lennard L, Singleton HJ. High-performance liquid chromatographic assay of human red blood cell thiopurine methyltransferase activity. J Chromatogr B Biomed Appl. 1994;661:25-33.
24. Thomas CW, Myhre GM, Tschumper R, et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: A mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther. 2005;312:537-545.
25. Li B, Yu H, Zheng W, et al. Role of the guanosine triphosphatase Rac2 in T helper 1 cell differentiation. Science. 2000;288:2219-2222.
26. Roberts RL, Barclay ML. Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease. J Gastroenterol Hepatol. 2012;27:1546-1554.
27. Sandborn WJ. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl. 1998;225:92-99.
28. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53.
29. Elion GB. The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. Ann N Y Acad Sci. 1993;685:401-407.
30. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91:423-433.
31. Lichtenstein GR, Abreu MT, Cohen R, et al; American Gastroenterological Association. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130: 935-939.
32. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122:904-915.
33. Neurath MF, Kiesslich R, Teichgraber U, et al. 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. Clin Gastroenterol Hepatol. 2005;3: 1007-1014.
34. Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004;2:731-743.
35. Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005; 100:2239-2247.
36. Roblin X, Serre-Debeauvais F, Phelip JM, et al. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther. 2005;21:829-839.
37. Achkar JP, Stevens T, Easley K, et al. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:339-345.
38. Morales A, Salguti S, Miao CL, et al. Relationship between 6- mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:380-385.
39. Dong XW, Zheng Q, Zhu MM, et al. Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. World J Gastroenterol. 2010;16:3187-3195.
40. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651-662.
41. Katsanos K, Tsianos E. Azathioprine/6-mercaptopurine toxicity: The role of the TPMT gene. Ann Gastroenterol. 2007;20:251-264.
42. Hon YY, Fessing MY, Pui CH, et al. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet. 1999;8: 371-376.
43. Snow JL, Gibson LE. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol. 1995;32:114-116.
44. Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: A review. Am J Gastroenterol. 2008; 103:1783-1800.
45. Robinson M. Optimizing therapy for inflammatory bowel disease. Am J Gastroenterol. 1997;92(12 suppl):12S-17S.
46. Winter JW, Gaffney D, Shapiro D, et al. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2007;25:1069-1077.
47. Lees CW, Maan AK, Hansoti B, et al. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:220-227.
48. Kuriyama M, Kato J, Suzuki H, et al. Tolerability and usefulness of mercaptopurine in azathioprine-intolerant Japanese patients with ulcerative colitis. Dig Endosc. 2010;22:289-296.
49. Nagy F, Molnar T, Szepes Z, et al. Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease. World J Gastroenterol. 2008;14:4342-4346.
50. Domenech E, Nos P, Papo M, et al. 6-mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scand J Gastroenterol. 2005;40:52-55.
51. McGovern DP, Travis SP, Duley J, et al. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology. 2002;122:838-839.
52. Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6- mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther. 2000;14:1561-1565.
53. Korelitz BI, Zlatanic J, Goel F, et al. Allergic reactions to 6- mercaptopurine during treatment of inflammatory bowel disease. J Clin Gastroenterol. 1999;28:341-344.
54. Korelitz BI, Reddy B, Bratcher J. Desensitization of patients with allergic reactions to immunosuppressives in the treatment of inflammatory bowel disease. Expert Opin Drug Saf. 2010;9:379-382.
55. Lavaud F, Abdelli N, Thiefin G. Successful desensitization for azathioprine skin rash in a patient with severe Crohn's disease. Dig Dis Sci. 1997;42:823.
56. Mutinga M, Castells M, Horan R, et al. Successful desensitization to 6- mercaptopurine in a patient with Crohn's disease. Am J Gastroenterol. 2000;95:1383-1384.
57. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut. 2002;51:143-146.
58. Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6- Thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol. 1998;42:266-272.
59. Brem R, Karran P. Oxidation-mediated DNA cross-linking contributes to the toxicity of 6-thioguanine in human cells. Cancer Res. 2012;72:4787- 4795.
60. Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer. 1993;68:186-190.
61. Bonaz B, Boitard J, Marteau P, et al. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol Ther. 2003;18:401-408.
62. Almer SH, Hjortswang H, Hindorf U. 6-thioguanine therapy in Crohn's disease: observational data in Swedish patients. Dig Liver Dis. 2009;41: 194-200.
63. Broxson EH, Dole M, Wong R, et al. Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy. Pediatr Blood Cancer. 2005;44:226-231.
64. Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis. 2001;7:181-189.
65. Seiderer J, Zech CJ, Reinisch W, et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol. 2005;43:303-309.
66. Teml A, Schwab M, Hommes DW, et al. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease. Wien Klin Wochenschr. 2007;119:519-526.
67. Curkovic I, Rentsch KM, Frei P, et al. Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations. Eur J Clin Pharmacol. 2013;69:1521-1531.
68. Hoentjen F, Hanauer SB, deBoer NK, et al. Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction. Dig Dis Sci. 2012;57: 250-253.
69. Appell ML, Wagner A, Hindorf U. A skewed thiopurine metabolism is a common clinical phenomenon that can be successfully managed with a combination of low-dose azathioprine and allopurinol. J Crohns Colitis. 2013;7:510-513.
70. Dore M, Frenette AJ, Mansour AM, et al. Febuxostat as a novel option to optimize thiopurines' metabolism in patients with inadequate metabolite levels. Ann Pharmacother. 2014;48:648-651.
71. Ansari A, Patel N, Sanderson J, et al. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:640-647.
72. Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005;22:441-446.
73. Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007;5:209-214.
74. Seinen ML, van Asseldonk DP, de Boer NK, et al. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study. J Crohns Colitis. 2013;7:812-819.
75. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121-1125.
76. Blaker PA, Arenas-Hernandez M, Smith MA, et al. Mechanism of allopurinol induced TPMT inhibition. Biochem Pharmacol. 2013;86:539-547.
77. Seinen ML, deBoer NK, Smid K, et al. Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during low-dose thiopurine therapy: preliminary data of an ongoing series. Nucleosides Nucleotides Nucleic Acids. 2011;30:1085-1090.
78. Chocair P, Duley J, Simmonds HA, et al. Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet. 1993;342:83-84.
79. Witte TN, Ginsberg AL. Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: A review of four cases and the literature. Can J Gastroenterol. 2008;22:181-185.
80. Min MX, Weinberg DI, McCabe RP. Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use. J Clin Pharm Ther. 2014;39:107-111.
81. Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:363-369.
82. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: A meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881.
83. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: An open randomised trial. Lancet. 2008;371:660-667.
84. Tozer P, Ng SC, Siddiqui MR, et al. Long-term MRI-guided combined anti-TNF-alpha and thiopurine therapy for Crohn's perianal fistulas. Inflamm Bowel Dis. 2012;18:1825-1834.
85. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
86. Teichgraber U, Atreya I, Atreya R, et al. Infliximab treatment induces levels of the active azathioprine metabolite TGTP in Crohn's disease. Inflamm Bowel Dis. 2013;19:E54-E55.
87. Shih DQ, Yoon JL, Huang BL, et al. Potential synergism between anti- TNF and thiopurine therapy: increased thiopurine metabolites by anti- TNF (abstract). Gastroenterology. 2013;144:S772.
88. Yoon JSD. Modification of thiopurine metabolism by anti-TNF therapy (abstract).
89. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10: CD000544.
90. Actis GC, Pellicano R, Rizzetto M, et al. Individually administered or coprescribed thiopurines and mesalamines for inflammatory bowel disease. World J Gastroenterol. 2009;15:1420-1426.
91. de Graaf P, de Boer NK, Wong DR, et al. Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: A prospective study in patients under steady thiopurine therapy. Br J Pharmacol. 2010;160:1083-1091.
92. Gao X, Zhang FB, Ding L, et al. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol. 2012;24:958-964.
93. Shih DQ, Nguyen M, Zheng L, et al. Split-dose administration of thiopurine drugs: A novel and effective strategy for managing preferential 6-MMP metabolism. Aliment Pharmacol Ther. 2012;36:449-458.
94. Knipp S, Hildebrandt B, Richter J, et al. Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. Haematologica. 2005;90:691-693.
95. Vos AC, Bakkal N, Minnee RC, et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study. Inflamm Bowel Dis. 2011;17:1837-1845.